Inventor

MERGHOUB TAHA

US44 patents

⚠️ This page may combine multiple inventors who share the name “MERGHOUB TAHA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

MERGHOUB TAHA

AGENUS INC

Anti-GITR antibodies and methods of use thereof

Anti-OX40 antibodies

Anti-GITR antibodies and methods of use thereof

Anti-CTLA-4 antibodies and methods of use thereof

Anti-CTLA-4 antibodies and methods of use thereof

Antibodies and methods of use thereof

Anti-CTLA-4 antibodies and methods of use thereof

Anti-PD-1 antibodies and methods of use thereof

Anti-CTLA-4 antibodies and methods of use thereof

Anti-CTLA-4 antibodies and methods of use thereof

Nucleic acids encoding anti-OX40 antibodies

Anti-GITR antibodies and methods of use thereof

Anti-CTLA-4 antibodies and methods of use thereof

Anti-PD-1 antibodies and methods of use thereof

Vectors comprising nucleic acids encoding anti-OX40 antibodies

Anti-GITR antibodies and methods of use thereof

Antibodies and methods of use thereof

Methods of administering anti-OX40 antibodies

Antibodies and methods of use thereof

Anti-OX40 antibodies

Anti-GITR antibodies and methods of use thereof

Anti-CTLA-4 antibodies and methods of use thereof

Anti-GITR antibodies and methods of use thereof

Anti-CTLA-4 antibodies and methods of use thereof

Anti-GITR antibodies and methods of use thereof

Anti-OX40 antibodies and anti-GITR antibodies

Anti-PD-1 antibodies and methods of use thereof

MEMORIAL SLOAN KETTERING CANCER CENTER

Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors

Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors

Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy

Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors

Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors

Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy

Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy

Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors

Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy

Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors

Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors

Vaccinia virus mutants useful for cancer immunotherapy

Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors

Vaccinia virus mutants useful for cancer immunotherapy

Recombinant poxviruses for cancer immunotherapy

Methods and compositions for treatment of pancreatic cancer

ICAHN SCHOOL MED MOUNT SINAI

Neoantigens and uses thereof for treating cancer